Abstract
Voltage-gated sodium channels are encoded by a family of ten structurally-related genes that are expressed in spatially and temporally distinct patterns, mainly in excitable tissues. They underlie electrical signalling in nerve and muscle. It has long been known that sodium channel blockers are anaesthetics as well as powerful analgesics when delivered at low concentrations. In addition, cardiac arrhythmias and epileptic activity can be treated with sodium channel blockers. As we have learned more about the sub-types of sodium channels and their distribution, new therapeutic opportunities have suggested themselves. There are indications that sodium channel blockers may also be useful in affective disorders and schizophrenia. The production of tissue-specific and eventually inducible knock out mice as well as genetic studies has proved useful in understanding the specialised role of individual types of sodium channels. The development of sub-type specific blockers has proved slower than anticipated, although the properties of naturally occurring toxin blockers suggest that subtype-specific blockers of sodium channels could be very useful clinically in the treatment of pain.
Current Topics in Medicinal Chemistry
Title: Voltage-Gated Sodium Channel Blockers; Target Validation and Therapeutic Potential
Volume: 5 Issue: 6
Author(s): John N. Wood and James Boorman
Affiliation:
Abstract: Voltage-gated sodium channels are encoded by a family of ten structurally-related genes that are expressed in spatially and temporally distinct patterns, mainly in excitable tissues. They underlie electrical signalling in nerve and muscle. It has long been known that sodium channel blockers are anaesthetics as well as powerful analgesics when delivered at low concentrations. In addition, cardiac arrhythmias and epileptic activity can be treated with sodium channel blockers. As we have learned more about the sub-types of sodium channels and their distribution, new therapeutic opportunities have suggested themselves. There are indications that sodium channel blockers may also be useful in affective disorders and schizophrenia. The production of tissue-specific and eventually inducible knock out mice as well as genetic studies has proved useful in understanding the specialised role of individual types of sodium channels. The development of sub-type specific blockers has proved slower than anticipated, although the properties of naturally occurring toxin blockers suggest that subtype-specific blockers of sodium channels could be very useful clinically in the treatment of pain.
Export Options
About this article
Cite this article as:
John N. Wood and James Boorman , Voltage-Gated Sodium Channel Blockers; Target Validation and Therapeutic Potential, Current Topics in Medicinal Chemistry 2005; 5 (6) . https://dx.doi.org/10.2174/1568026054367584
DOI https://dx.doi.org/10.2174/1568026054367584 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serum Thiol-Disulphide Levels in Epileptic Pediatric Patients
Combinatorial Chemistry & High Throughput Screening Natural Plants with Antiepileptic Activity-The Present and Future Perspectives
The Natural Products Journal Migraine and Central Sensitization: Clinical Features, Main Comorbidities and Therapeutic Perspectives
Current Rheumatology Reviews A One Pot Green Synthesis of 3,4 Dihydropyrimidin-2-(1H)-ones/Thiones Catalyzed By MgO-ZrO<sub>2</sub> Under Solvent-Free Conditions
Letters in Organic Chemistry Cell Culture Models of Oxidative Stress and Injury in the Central Nervous System
Current Neurovascular Research Gut Microbiota Regulate Astrocytic Functions in the Brain: Possible Therapeutic Consequences
Current Neuropharmacology An EJC Factor RBM8a Regulates Anxiety Behaviors
Current Molecular Medicine Vagus nerve stimulation in treating depression: A tale of two stories.
Current Molecular Medicine Preface [Hot Topic: Rational Drug Design and The Discovery of the 1,2,3-Triazolines as a Unique Class of Anticonvulsants and Antiischemic Agents (Guest Editor: Pankaja K. Kadaba)]
Current Medicinal Chemistry Targeting the Brain: Advances in Drug Delivery
Current Pharmaceutical Biotechnology Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Drug Transporters in Chemotherapy Induced Peripheral Neurotoxicity:Current Knowledge and Clinical Implications
Current Medicinal Chemistry Review of Treatment for Cocaine Dependence
Current Drug Abuse Reviews Sao Paulo Research Conference on Molecular Medicine and Pharmacogenetics, A Joint Meeting with the IUPHAR Sub-Committee on Pharmacogenetics and the Brazilian Pharmacogenetics Network, Sao Paulo, Brazil, September 18-20, 2008
Current Pharmacogenomics and Personalized Medicine Antimicrobial Drug Interactions in the Critically Ill Patients
Current Clinical Pharmacology Genome-Scale Technologies Foster Advances in Neurological and Behavioral Research
Current Psychiatry Reviews Warfarin Dosing and the Promise of Pharmacogenomics
Current Clinical Pharmacology Evaluation of the Influence of the Conjugation Site of the Chelator Agent HYNIC to GLP1 Antagonist Radiotracer for Insulinoma Diagnosis
Current Radiopharmaceuticals Recent Developments in Oxidative Processes in Steroid Chemistry
Current Organic Chemistry